• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Related Links
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of High Institute of Public Health
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 55 (2025)
Volume Volume 54 (2024)
Volume Volume 53 (2023)
Volume Volume 52 (2022)
Volume Volume 51 (2021)
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 50 (2020)
Volume Volume 49 (2019)
Volume Volume 48 (2018)
Volume Volume 47 (2017)
Volume Volume 46 (2016)
Volume Volume 45 (2015)
Volume Volume 44 (2014)
Volume Volume 43 (2013)
Volume Volume 42 (2012)
Volume Volume 41 (2011)
Volume Volume 40 (2010)
Volume Volume 39 (2009)
Volume Volume 38 (2008)
Volume Volume 37 (2007)
Volume Volume 36 (2006)
Volume Volume 35 (2005)
Volume Volume 34 (2004)
Volume Volume 33 (2003)
Volume Volume 32 (2002)
Volume Volume 31 (2001)
Volume Volume 30 (2000)
Volume Volume 29 (1999)
El-Nimr, N. (2021). Merits and Demerits of COVID-19 Vaccines. Journal of High Institute of Public Health, 51(1), 1-9. doi: 10.21608/jhiph.2021.150582
Nessrin A. El-Nimr. "Merits and Demerits of COVID-19 Vaccines". Journal of High Institute of Public Health, 51, 1, 2021, 1-9. doi: 10.21608/jhiph.2021.150582
El-Nimr, N. (2021). 'Merits and Demerits of COVID-19 Vaccines', Journal of High Institute of Public Health, 51(1), pp. 1-9. doi: 10.21608/jhiph.2021.150582
El-Nimr, N. Merits and Demerits of COVID-19 Vaccines. Journal of High Institute of Public Health, 2021; 51(1): 1-9. doi: 10.21608/jhiph.2021.150582

Merits and Demerits of COVID-19 Vaccines

Article 1, Volume 51, Issue 1, April 2021, Page 1-9  XML PDF (345.88 K)
Document Type: Review Article
DOI: 10.21608/jhiph.2021.150582
View on SCiNiTO View on SCiNiTO
Author
Nessrin A. El-Nimr email
Department of Epidemiology, High Institute of Public Health, Alexandria University, Egypt
Abstract
The COVID-19 pandemic caused by the novel coronavirus (SARS-CoV-2) continues to reshape the globe. It is more than a year since the virus first emerged, yet the vast majority of people are still vulnerable. The current response to the COVID-19 pandemic involves aggressive implementation of containment, suppression, and mitigation strategies causing devastating social, economic and political crises. The restrictions on our lives are the only thing holding the virus in check. The world cannot return to normal without safe and effective vaccines against COVID-19 along with a coordinated global vaccination program. Vaccines remain the safest, most cost-effective protection against disease. Unprecedented data sharing and collaborative team efforts are breaking down barriers in an attempt to reduce the time of vaccine development. An ideal COVID-19 vaccine should be safe, provide long-lasting protection, protect not only against disease but prevent virus transmission to others, be able to be produced quickly and in large quantities, be easily stored, transported and administered. The global COVID-19 vaccine pipeline is currently expanding on a daily basis. Multiple platforms are being used for producing vaccines at pandemic speed. Each platform has its own merits, demerits and challenges and it is unlikely that any single platform on its own will constitute a solution for the ongoing COVID-19 pandemic.
Keywords
COVID-19; vaccines
Statistics
Article View: 6,369
PDF Download: 3,113
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.